Format

Send to

Choose Destination
Anticancer Res. 2010 Aug;30(8):3125-8.

Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma.

Author information

1
Hanakoganei Clinic, 1-18-25 Hanakoganei-minami-cho, Kodaira, Tokyo, 187-0003 Japan. question@onnetsu.com

Abstract

We describe the case of a patient with terminal adenocarcinoma of the lung with no response to lymphokine-activated killer (LAK) cell therapy alone who distinctly responded clinically to a combination of high-dose glucocorticoids (GC) and LAK cell therapy, administered by chance. However, after decreasing the dose of GC because of gastrointestinal bleeding caused by the high-dose treatment, there was no response on restarting GC plus LAK cell therapy. The clinical course of this case strongly suggests that local inflammation in the vicinity of tumors should be adequately suppressed in patients with advanced cancer who receive immunotherapy.

PMID:
20871030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center